#United States #Foster City #Gilead Sciences #Veklury #HIV Treatments

Gilead Sciences' Remarkable Q2 2026 Performance Report

Gilead Sciences, headquartered in Foster City, California, has recently shared its financial performance for the second quarter of 2026, indicating promising growth within its product portfolio. The company’s CEO, Daniel O'Day, emphasized the significant 10% increase in its core business sales, attributing it largely to the strength of its HIV therapies, alongside its oncology products Trudelvy (sacituzumab govitecan) and Livdelzi (seladelpar).

Overall, Gilead’s revenue for Q2 2026 reached $7.8 billion, marking a 10% rise compared to the same period the previous year. Notably, the sales from HIV products alone grew by 12%, reflecting the sustained success of treatment options and rapid expansion in pre-exposure prophylaxis (PrEP) initiatives. O'Day expressed optimism regarding the anticipated launches of two new products in the oncology and HIV sectors by the latter half of the year, supported by three new FDA approvals and positive Phase III trial updates.

Key Highlights of Q2 2026 Performance

• - Total Revenue: For Q2 2026, Gilead reported total revenues of $7.8 billion, driven primarily by increases in its HIV product sales, Trudelvy, and Livdelzi. However, this growth was partly tempered by declines in sales from Veklury (remdesivir), cell therapy products, and chronic hepatitis C virus (HCV) products.
• - Earnings Report: The diluted loss per share was $(8.45) compared to a profit of $1.56 in Q2 2025. The significant loss was attributed to in-process research and development (IPR&D) expenses related to recent acquisitions, which impacted earnings by approximately $9.08 per share.
• - Cash Flows: Gilead generated $3.6 billion in operating cash flow during this period, despite a reduced cash and cash equivalents balance, which decreased to $3.2 billion from $10.6 billion at the end of 2025. This decrease was largely due to cash outflows associated with recent acquisitions, debt repayments, dividend payments, and stock repurchases.
• - Product Sales Growth: Excluding Veklury, Gilead's product sales amounted to $7.6 billion, an increase of 10% compared to Q2 2025. The growth was predominantly propelled by HIV product revenues, which reached $5.7 billion, reflecting a 12% increase driven by higher average selling prices and demand.
• - Challenges in HCV and Cell Therapies: Notably, Veklury's revenue saw an 81% decline year-over-year to $23 million, primarily driven by a decrease in COVID-19 related hospitalizations. Additionally, sales from cell therapy products also faced challenges, decreasing 14% due to competitive pressures.

Forecast and Future Outlook

For the remainder of 2026, Gilead anticipates total product sales in the range of $30.1 to $30.4 billion, with substantial growth expected for its HIV therapies and oncology products. The company aims to navigate potential challenges while maximizing opportunities through continued product innovation and development.

Strategic Acquisitions and Innovations

On the acquisition front, Gilead has made strategic moves, including the completion of acquiring Arcellx, Tubulis, and Ouro Medicines. Such acquisitions will fortify its pipeline for innovative therapies targeting cancer and autoimmune diseases. Furthermore, Gilead is collaborating with the WHO to provide financial support and resources in combating visceral leishmaniasis.

In conclusion, Gilead Sciences continues to demonstrate resilience amidst industry challenges, with promising growth prospects driven by its strong product portfolio and strategic initiatives aimed at addressing serious health conditions worldwide.